Mutant KRAS is a druggable target for pancreatic cancer

Pancreatic ductal adenocarcinoma (PDA) represents an unmet therapeutic challenge. PDA is addicted to the activity of the mutated KRAS oncogene which is considered so far an undruggable therapeutic target. We propose an approach to target KRAS effectively in patients using RNA interference. To meet t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Zorde Khvalevsky, Elina, Gabai, Racheli, Rachmut, Itzhak Haim, Horwitz, Elad, Brunschwig, Zivia, Orbach, Ariel, Shemi, Adva, Golan, Talia, Domb, Abraham J., Yavin, Eylon, Giladi, Hilla, Rivkin, Ludmila, Simerzin, Alina, Eliakim, Rami, Khalaileh, Abed, Hubert, Ayala, Lahav, Maor, Kopelman, Yael, Goldin, Eran, Dancour, Alan, Hants, Yael, Arbel-Alon, Sagit, Abramovitch, Rinat, Shemi, Amotz, Galun, Eithan
Format: Artigo
Idioma:Inglês
Publicat: National Academy of Sciences 2013
Matèries:
Biological Sciences
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3870687/
https://ncbi.nlm.nih.gov/pubmed/24297898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1314307110
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars